Fennec Pharmaceuticals Inc. (FRX.TO) TSX
Currency In CAD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In CAD
Address
68 TW Alexander Drive
Research Triangle Park, NC 27709
United States of America (the)
Phone
919 636 4530
Website
Sector
Healthcare
Industry
Biotechnology
Employees
32
First IPO Date
June 12, 2001
| Name | Title | Pay | Year Born |
| Jeffrey S. Hackman | Chief Executive Officer & Director | 895,603 | 1963 |
| Pierre S. Sayad | Chief Medical Officer | 657,463 | N/A |
| Robert C. Andrade | Chief Financial Officer | 782,933 | 1975 |
| Mark Gowland | Controller | 0 | N/A |
| Terry Evans | Chief Commercial Officer | 0 | N/A |
| Christiana Cioffi | Chief Strategy Officer | 0 | N/A |
| Lei Fang | President of Pharstat Inc | 0 | N/A |
Fennec Pharmaceuticals Inc., a biopharmaceutical firm established in 1996, operates from its base in Research Triangle Park, North Carolina. The company's lead investigational compound, PEDMARK, is a sodium thiosulfate formulation currently undergoing clinical development. This product candidate is specifically engineered to protect young cancer patients from platinum-induced ototoxicity, a form of hearing loss caused by chemotherapy. Previously known as Adherex Technologies Inc., the company officially rebranded to Fennec Pharmaceuticals Inc. in September 2014.